治験レーダーAI
治験 NCT06735521 (CMR_TCPC)(対象:単心室心、微小血管機能障害、心不全、Magnetic Resonance)は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation (CMR_TCPC)

募集中
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます!「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT06735521 (CMR_TCPC) は 観察研究 臨床試験 で、単心室心、微小血管機能障害、心不全、Magnetic Resonance に関するものです。現在は 募集中 で、2024年4月15日 から開始しています。30 名の参加者 の募集が計画されています。この治験は カロリンスカ研究所 によって主催され、2025年9月1日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2024年12月16日 です。
概要
Univentricular heart (UVH) is a severe congenital heart disease. Accurate advanced non-invasive diagnostic methods is limited. Cardiovascular magnetic resonance (CMR) imaging has evolved as a particularly useful tool for the study of patients with adult congenital heart disease (ACHD) considering its ability to determine detailed anatomy and detect early cardiac dysfunction without the need for radiation exposure. Most of contemporary treatment recommendations are based on consensus opinions/documents and small studies from local, or national registries. Improved knowledge is needed in all these areas to facilitate clinical decisions regarding treatment, monitoring and follow-up.

This study seeks to answer if early detection of deterioration in cardiac function, venous pressure and microvascular dysfunction can identify patients before the symptoms progress and thus help to initiate early treatment. The hypothesis is that quantitative myocardial stress-perfusion maps improves the pathophysiological insight in patients with UVH.

The overall goal with this research proposal is to implement combined advanced CMR imaging for a comprehensive non-invasive mapping of functional cardiovascular behavior in patients with complex UVH disease. The outcome of this research may benefit this young adult patient population due to early detection of cardiac disease, less hospitalizations because of heart failure, and eventually decrease morbidity and mortality.

詳細説明
CMR is performed supine with a Magnetom Aera® 1.5 Tesla (T) scanner (Siemens Healthcare, Erlangen, Germany), with a phased-array 18-channel body matrix coil and a spine matrix coil. A venous blood sample is drawn to determine hematocrit and blood creatinine prior to imaging. Full coverage retrospective electrocardiographic (ECG)-gated balanced steady state free precession (bSSFP) cine imaging is acquired in standard three long-axis and short-axis slices. Typical imaging parameters are flip angle 68°, pixel size 1.4 × 1.9 mm2, slice thickness 8.0 mm, echo time (TE)/repetition time (TR) 1.19/37.05 ms, matrix size 256 × 144 and field of view (FOV) 360 × 270 mm2.

Using first-pass perfusion imaging, quantitative perfusion maps (ml/min/g) are acquired in one short-axis and one long-axis slice (mid-ventricular, 2-chamber) during administration of an intravenous contrast-agent bolus (0.05 mmol/kg, gadobutrol, Gadovist, Bayer AB, Solna, Sweden), during adenosine infusion (110 µg/kg/min or increased according to clinical routine to 140 µg/kg/min in the absence of adequate response to adenosine (Adenosine, Life Medical AB, Stockholm) and in subsequent rest. Adenosine response is assessed clinically based on symptoms and heart rate response. Adenosine and contrast agent are administered in two different cannulas. Subjects abstained from caffeine for 24 hours prior to CMR examination. A distributed tissue exchange model is used to compute the perfusion maps and the Gadgetron (reconstruction computer) inline perfusion mapping software is used to generate the perfusion maps.Typical imaging parameters were bSSFP single shot readout, flip angel 50°, slice thickness 8.0 mm, TE/TR 1.04/2.5 ms, bandwidth 1085 Hz/pixel, FOV 360 × 270 mm2 and saturation delay/trigger delay (TD) 95/40 ms.

公式タイトル

Att Överleva Och Leva Som Vuxen Med Enkammarhjärta I Sverige

疾患/病気
単心室心微小血管機能障害心不全Magnetic Resonance
刊行物
この臨床試験について発表された科学記事と研究論文:
その他の研究識別子
  • CMR_TCPC
  • Dnr 2022-04574-01
NCT番号
開始日
2024-04-15
最終更新日
2024-12-16
終了予定日
2025-09-01
目標参加者数
30
試験の種類
観察研究
状況
募集中
キーワード
Fontan circulation
CMR
stress-perfusion
tissue characterization
univentricle heart
TCPC
群(アーム)/介入
参加グループ/群介入/治療法
Univentricle heart, operated with TCPC (total cavo pulmonary connection)
Cardiac Magnetic Resonance Stress-perfusion
Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium. Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest.
主要評価項目
評価指標指標の説明時間枠
Detection of microvascular dysfunction in patients with UVH
This project aims to evaluate microvascular dysfunction using quantitative stress-perfusion CMR in patients with different morphological systemic chamber (left vs right).
Through study completion, an average of 1 year
副次評価項目
評価指標指標の説明時間枠
To detect and compare tissue characterization.
Investigate whether positive findings in tissue characterization is higher in different systemic ventricles (left vs right) using T1 and T2-mapping, LGE (late gadolinium enhancement, myocardial scar).
Through study completion, an average of 1 year
適格基準

対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
  • Patients who had undergone total cavo-pulmonary connection (TCPC) surgery resulting in Fontan circulation.
  • NYHA (New York Heart Assosiation) class I-II.
  • Understanding the study information (signed informed consent).
  • >18 years old.

  • Device therapy (pacemaker, ICD).
  • Failing Fontan (NYHA III-IV).
  • Kidney failure (GFR<30ml/h).
  • Arrythmia (atrial fibrillation).
  • Pregnancy.
Karolinska Institutet logoカロリンスカ研究所
Karolinska University Hospital logoKarolinska University Hospital
責任者
Peder Sörensson, 研究責任者, Senior Consultant in Cardiology, Karolinska Institutet
試験中央連絡先
連絡先: Peder Sorensson, MD, Associate professor, +46 731 400059, [email protected]
連絡先: Ayse-Gul Ozturk, MD, [email protected]
1 1カ国の場所
Karolinska University Hospital, Stockholm, 17176, Sweden
Peder Sorensson, MD, Associate professor, 連絡先, +46 731 400059, [email protected]
Ayse-Gul Ozturk, MD, 連絡先, +46 72 578 02 72, [email protected]
Peder Sorensson, MD, Associate professor, 連絡先
募集中